Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... infections but also leads to the deterioration of ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias ...

At the end of the treatment evaluation, they also looked at progression ... and dexamethasone for transplantation-eligible ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

The following is a summary of “Evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective ...

Newer treatments, including anti-CD38 monoclonal antibodies and immunomodulating agents, are becoming standard in multiple myeloma management. In patients with relapsed or refractory multiple myeloma, ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...